The Trump administration just shook up the cannabis world with a fast move to ease federal rules on marijuana. State-licensed medical pot now shifts to Schedule III, dodging a brutal tax penalty under Section 280E. But recreational sellers get no help yet, leaving most businesses in the lurch as they fight sky-high taxes.
Acting Attorney General Todd Blanche signed the order on April 23, 2026. It hits two targets at once. First, FDA-approved cannabis drugs move from Schedule I to Schedule III without delay. Second, marijuana grown or sold under state medical licenses joins them.
This change accepts cannabis has real medical value. It clears roadblocks for research and lets doctors prescribe it more freely in some cases. State medical operators can now register with the DEA in 60 days. That opens doors to move products across state lines for studies or patients.
Medical cannabis firms stand to save millions by deducting everyday costs like rent and wages. Before this, they paid taxes on gross sales, not profits. Effective rates topped 70% in many spots. The order urges the Treasury to eye refunds for past years too.
One short win. Relief starts now for pure medical players.
The 280E Tax Trap Hits Hard
Section 280E of the tax code packs a punch. It blocks deductions for any business touching Schedule I or II drugs. Cannabis stayed in Schedule I for decades. Sellers subtract only cost of goods sold. Everything else, from marketing to security, adds to taxable income.
Whitney Economics crunched numbers last year. Legal cannabis operators paid $2.24 billion extra in federal taxes due to 280E in 2025 alone. That cash drain starved growth and fueled closures.
Big multi-state operators feel it worst. Trulieve owes the IRS $630 million. Curaleaf faces $531 million. Verano Holdings carries $378 million, and Cresco Labs $171 million. These debts push firms toward splits or bankruptcies.
Owners say it feels like a racket. Pay Uncle Sam on every dime before bills, while rivals deduct freely. Small shops scrape by on thin margins. Relief would free billions for jobs and expansion.
Medical Gets Relief, Rec Stays Stuck
Here’s the catch. The order covers only state medical licenses. Adult-use pot, the market powerhouse, sits in Schedule I. In 2025, recreational sales hit $23.9 billion. Medical trailed at $7.6 billion. Total market: $31.5 billion.
Most big players mix both lines. They must split books now. IRS guidance comes soon on how to carve out medical deductions. Treasury says apportion expenses by activity.
| Company | Est. 280E Tax Debt (2026 filings) |
|---|---|
| Trulieve | $630 million |
| Curaleaf | $531 million |
| Verano | $378 million |
| Cresco | $171 million |
Pure rec shops see zero change. They keep paying 70% rates. Medical-only firms cheer. Trulieve CEO Kim Rivers called it a research boost. Curaleaf’s Boris Jordan eyes patient growth.
Mixed ops face headaches. Track separate costs or risk audits. One operator noted it could take months to sort.
This split creates winners and losers overnight.
Hurdles Block Full Tax Freedom
A DEA hearing kicks off June 29, 2026. It eyes all marijuana for Schedule III. Wraps by mid-July. But lawsuits loom. Foes may fight the medical carve-out. Industry pushes for the full shift.
IRS fights back too. In New Mexico Top Organics tax court case, agents defend 280E hard. They eye penalties up to 20% on challengers. Taxpayers claim reasonable basis, but courts set high bars.
No full legalization here. Banks still shy away. Interstate sales banned. Illicit markets thrive.
Limited relief sparks hope but warns of pitfalls. Stocks jumped: Tilray up 14%, Canopy Growth 21%. Yet experts urge caution. Relief hits medical first, rec waits. Operators prep for audits and splits.
Industry voices mix joy and grit. NCIA’s Adam Rosenberg demands retro fixes for small guys. NORML’s Paul Armentano wants total removal from drug schedules.
Change brews slow in Washington. Cannabis firms eye cash flow gains. Patients gain access. But the tax war rages on.
This partial win lifts medical operators from a crushing load, yet spotlights the recreational giant left paying full price. Families running dispensaries dream of fair play. Investors bet on the next shoe drop.